Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland Maj Institute of Pharmacology, Polish Academy of ...

TLR7/8 have been implicated in the initiation and progression of lupus, a disease associated with defects in the clearance of apoptotic debris which can activate these receptors. However, the effects ...